Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1492–1494. doi: 10.1128/aac.35.7.1492

Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.

J L Schmit 1, L Hary 1, P Bou 1, H Renaud 1, P F Westeel 1, M Andrejak 1, A Fournier 1
PMCID: PMC245198  PMID: 1929314

Abstract

Comparison of plasma and dialysate concentrations of pefloxacin after intravenous, oral, or intraperitoneal administration shows excellent bidirectional diffusion of the quinolone through the peritoneal membrane, demonstrating that therapeutical concentrations can be achieved in the dialysate after intravenous or oral administration. In this study, the half-life of the drug was 18.8 +/- 1.4 h, i.e., apparently longer than that reported for normal controls or uremic patients on hemodialysis.

Full text

PDF
1492

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Denis F., Mounier M., Lagarde C., Benevent D. Traitement des péritonites des insuffisants rénaux en dialyse péritonéale continue ambulatoire par la péfloxacine. Résultats et pharmacocinétique. Pathol Biol (Paris) 1987 May;35(5):652–655. [PubMed] [Google Scholar]
  2. Frydman A. M., Le Roux Y., Lefebvre M. A., Djebbar F., Fourtillan J. B., Gaillot J. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother. 1986 Apr;17 (Suppl B):65–79. doi: 10.1093/jac/17.suppl_b.65. [DOI] [PubMed] [Google Scholar]
  3. Gokal R., Ramos J. M., Francis D. M., Ferner R. E., Goodship T. H., Proud G., Bint A. J., Ward M. K., Kerr D. N. Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies. Lancet. 1982 Dec 18;2(8312):1388–1391. doi: 10.1016/s0140-6736(82)91282-x. [DOI] [PubMed] [Google Scholar]
  4. Höffken G., Borner K., Glatzel P. D., Koeppe P., Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985 Jun;4(3):345–345. doi: 10.1007/BF02013667. [DOI] [PubMed] [Google Scholar]
  5. Höffler D., Schäfer I., Koeppe P., Sörgel F. Pharmacokinetics of pefloxacin in normal and impaired renal function. Arzneimittelforschung. 1988 May;38(5):739–743. [PubMed] [Google Scholar]
  6. Janknegt R., Koelman J. H. Drug therapy in continuous ambulatory peritoneal dialysis patients. Pharm Weekbl Sci. 1987 Apr 24;9(2):104–109. doi: 10.1007/BF01960744. [DOI] [PubMed] [Google Scholar]
  7. Jungers P., Ganeval D., Hannedouche T., Prieur B., Montay G. Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. Eur J Clin Pharmacol. 1987;33(5):463–467. doi: 10.1007/BF00544236. [DOI] [PubMed] [Google Scholar]
  8. King A., Phillips I. The comparative in-vitro activity of pefloxacin. J Antimicrob Chemother. 1986 Apr;17 (Suppl B):1–10. doi: 10.1093/jac/17.suppl_b.1. [DOI] [PubMed] [Google Scholar]
  9. Matzke G. R., Abraham P. A., Halstenson C. E., Keane W. F. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther. 1985 Jul;38(1):31–36. doi: 10.1038/clpt.1985.130. [DOI] [PubMed] [Google Scholar]
  10. Montay G., Goueffon Y., Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463–472. doi: 10.1128/aac.25.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Montay G., Jacquot C., Bariety J., Cunci R. Pharmacokinetics of pefloxacin in renal insufficiency. Eur J Clin Pharmacol. 1985;29(3):345–349. doi: 10.1007/BF00544092. [DOI] [PubMed] [Google Scholar]
  12. Montay G., Tassel J. P. Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue. J Chromatogr. 1985 Apr 12;339(1):214–218. doi: 10.1016/s0378-4347(00)84647-2. [DOI] [PubMed] [Google Scholar]
  13. Nix D. E., Wilton J. H., Ronald B., Distlerath L., Williams V. C., Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother. 1990 Mar;34(3):432–435. doi: 10.1128/aac.34.3.432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Paton T. W., Cornish W. R., Manuel M. A., Hardy B. G. Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1985 Sep-Oct;10(5):404–425. doi: 10.2165/00003088-198510050-00003. [DOI] [PubMed] [Google Scholar]
  15. Prowant B., Nolph K., Ryan L., Twardowski Z., Khanna R. Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience. Nephron. 1986;43(2):105–109. doi: 10.1159/000183807. [DOI] [PubMed] [Google Scholar]
  16. Singlas E., Leroy A., Sultan E., Godin M., Moulin B., Taburet A. M., Dhib M., Fillastre J. P. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. Clin Pharmacokinet. 1990 Jul;19(1):67–79. doi: 10.2165/00003088-199019010-00005. [DOI] [PubMed] [Google Scholar]
  17. Vas S. I. Microbiologic aspects of chronic ambulatory peritoneal dialysis. Kidney Int. 1983 Jan;23(1):83–92. doi: 10.1038/ki.1983.15. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES